Comparison of ISG15, IL28B and USP18 mRNA levels in peripheral blood mononuclear cells of chronic hepatitis B virus infected patients and healthy individuals
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 1 (2019),
29 January 2019
,
Page 38-45
https://doi.org/10.22037/ghfbb.v0i0.1360
Abstract
Background: Despite the presence of an efficient vaccine for hepatitis B virus (HBV), it remains a public health challenge, worldwide. The effort to uncovering immune genes attributed to infection outcome is in undergone. The purpose of this study was to evaluate the expression level of Interferon-stimulated Gene 15 (ISG15), Interleukin28B (IL28B) and Ubiquitin specific peptidase 18 (USP18) genes in Peripheral Blood Mononuclear Cells (PBMCs) of patients with chronic active and inactive hepatitis B in comparison with healthy control individuals.
Materials and Methods: This Cross-sectional study was conducted on hepatitis B infected patients that were admitted to Clinic of Liver diseases, Shiraz, between January 2016-2017. Gene expression assay was performed on PBMCs of blood samples by the help of Real-time PCR method. The relative expression of each gene was calculated regarding 2-?Ct formula.
Results: Interleukin 28B gene expression showed no statistically significant difference between three studied groups. The expression level of ISG15 gene was significantly higher in the healthy control group compared to active (P= 0.0068) and inactive chronic subjects(P<0.0001). Similarly, USP18 expression level in the control group was also significantly higher compared to the active (P= 0.0228) and inactive chronic patients (P=0. 0226).
Conclusion: The results of this study showed that the expression level of ISG15 and USP18 but not IL28B were higher in healthy individuals than those infected with HBV. This difference expression may highlight the role of ISG15 and USP18 in immune-related mechanism HBV infection.
- Hepatitis B virus
- Innate Immunity
- ISG15
- IL28B
- USP18
How to Cite
References
Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007;16:403-6.
Shelmani HM, Karayiannis P, Ashtari S, Mahmanzar MA, Khanabadi B, Modami N, et al. Demographic changes of hepatitis B virus infection in Iran for the last two decades. Gastroenterol Hepatol Bed Bench 2017;10:S38.
Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-9.
Haghshenas MR, Arabi M, Mousavi T. Hepatitis B genotypes in iran. Materia socio-medica 2014;26:129.
Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, et al. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon 2013;13:e8351.
Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-68.
Aspinall E, Hawkins G, Fraser A, Hutchinson S, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational medicine. 2011;61(8):531-40.
Kgatle MM, Setshedi M. Immunopathogenesis of hepatitis B virus infection and related complications. EMJ Hepatol. 2016;4:84-92
Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016;16:509-23.
Hoan NX, Van TH, Giang DP, Toan NL, Meyer CG, Bock CT, et al. Interferon-stimulated gene 15 in hepatitis B-related liver diseases. Oncotarget 2016;7:67777-87.
Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011;31:1118-26.
Jones DM, Domingues P, Targett-Adams P, McLauchlan J. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J Gen Virol 2010;91:2238-48.
Li Y, Li S, Duan X, Liu B, Yang C, Zeng P, McGilvray I, Chen L. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev Med Virol 2014;24:332-42.
Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, et al. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol 1995;76:1749-61.
Kim MJ, Yoo JY. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J Immunol 2010;185:4311-8.
Kim JH, Luo JK, Zhang DE. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008;181:6467-72.
Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C, Zuo C. ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med 2015;8:17140-50.
Shi X, Chi X, Pan Y, Gao Y, Li W, Yang C, et al. IL28B is associated with outcomes of chronic HBV infection.
Yonsei Med J 2015;56:625-33.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat
Genet 2009;41:1100-4.
Farrell PJ, Broeze RJ, Lengyel P. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature. 1979 7;279:523-5.
Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterol 2012;142:513-20.
Liu LQ, Ilaria R Jr, Kingsley PD, Iwama A, van Etten RA, Palis J, et al. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999;19:3029-38.
Li L, Lei QS, Zhang SJ, Kong LN, Qin B. Suppression of USP18 potentiates the anti-HBV activity of interferon alpha in HepG2 2.15 cells via JAK/STAT signaling. Plos One 2016;11:e0156496.
Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, et al. Review team: world gastroenterology organisation global guideline hepatitis b:2015. J Clin Gastroenterol 2016;50:691-703.
Sarvari J, Mojtahedi Z, Kuramitsu Y, Malek Hosseini SA, Shahrabadi MS, Ghaderi A, et al. Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection. Oncol lett 2011;2:871.
Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012;36:104-14.
Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012;79:302-5.
Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010;202:1749-53.
Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. Plos One 2013;8:e58071.
Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 2012;61:1433-9.
Jeon YJ, Yoo HM, Chung CH. ISG15 and immune diseases. Biochim Biophys Acta 2010;1802:485-96.
Skaug B, Chen ZJ. Emerging role of ISG15 in antiviral immunity. Cell 2010;143:187-90.
Kim KI, Yan M, Malakhova O, Luo JK, Shen MF, Zou W, et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 2006;26:472-9.
Broering R, Zhang X, Kottilil S, Trippler M, Jiang M, Lu M, et al. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 2010;59:1111-9.
Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol 2017;66:897-909.
Hoan NX, Van TH, Giang DP, Toan NL, Meyer CG, Bock CT, et al. Interferon-stimulated gene 15 in hepatitis B-related liver diseases. Oncotarget 2016;7:67777-87.
Speer SD, Li Z, Buta S, Payelle-Brogard B, Qian L, Vigant F, et al. ISG15 deficiency and increased viral resistance in humans but not mice. Nat Commun 2016;7:11496.
Jiao B, Chen L. The role of USP18 in interferon signaling and inflammation. Cell Death Dis. 2012;3:e419.
Li L, Lei QS, Zhang SJ, Kong LN, Qin B. Suppression of usp18 potentiates the anti-hbv activity of interferon alpha in hepg2.2.15 cells via jak/stat signaling. Plos One 2016;11:e0156496.
Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A
;99:13825-30.
Rehermann B, Ed. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Seminars in liver disease. New York: Thieme Medical Publishers, Inc.; 2007.
Ayoobi F, Hassanshahi G, Zainodini N, Khorramdelazad H, Arababadi MK, Kennedy D. Reduced expression of TRIF in chronic HBV infected Iranian patients. Clin Res Hepatol Gastroenterol 2013;37:491-5.
Ebrahim M, Mirzaei V, Bidaki R, Shabani Z, Daneshvar H, Karimi-Googheri M, et al. Are rig-1 and mda5 expressions associated with chronic hbv infection? Viral Immunol 2015;28:504-8.
Dowran R, Sarvari J, Moattari A, Fattahi MR, Ramezani A, Hosseini SY. Analysis of TLR7, SOCS1 and ISG15 immune genes expression in the peripheral blood of responder and non-responder patients with chronic Hepatitis C. Gastroenterol Hepatol Bed Bench 2017;10:272.
- Abstract Viewed: 211 times
- PDF Downloaded: 116 times